June 17, 2021
PMLiVE
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront paym... See more »
986 Followers on Owler
bluebird bio
bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. Read more
President & CEO
Nick Leschly
Missing a competitor? Contribute!
Sangamo is the biggest rival of bluebird bio. Sangamo was founded in 1995, and its headquarters is in Brisbane, California. Sangamo operates in the Biotechnology industry. Sangamo has 351 fewer employees than bluebird bio.
Weigh-in!
Help the Owler community know moreTrending News for bluebird bio and bluebird bio's Competitors
June 18, 2021
MarketScreener
Lonza : and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an anti-IGF-1R Antibody for Autoimmune Diseases
(marketscreener.com) Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an ... See more »
June 18, 2021
PR Newswire
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care
BASEL, Switzerland, June 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced ... See more »
bluebird bio Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$241.7M
bluebird bio's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 499.5M. Over the last four quarters, bluebird bio's revenue has decreased by 93.6%. Specifically, in Q1 2021's revenue was $12.8M; in Q4 2020, it was $10.7M; in Q3 2020, it was $19.3M; in Q2 2020, bluebird bio's revenue was $198.9M.
bluebird bio Acquisitions
No recent acquisitions found related to bluebird bio
bluebird bio Funding History
Since bluebird bio was founded in 1992, it has participated in 8 rounds of funding. In total bluebird bio has raised $526.4M. bluebird bio's last funding round was on Dec 2016 for a total of $250.0M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
Post-IPO Equity
Dec 2016
$250M
-
IPO
Jun 2013
$116.1M
-
Grant
Oct 2012
$9.3M
Since bluebird bio was founded in 1992, it has participated in 8 rounds of funding. In total bluebird bio has raised $526.4M. bluebird bio's last funding round was on Dec 2016 for a total of $250.0M
bluebird bio Investments
No recent investments found related to bluebird bio
bluebird bio News
June 11, 2021MarketScreener
Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% (20/22) of evaluable pediatric patients under the age of 18 (Form 8-K)
(marketscreener.com) June 11, 2021- bluebird bio, Inc. today presented data from several studies of b... See more »
June 10, 2021WRAL TechWire
FDA gives OK to Bluebird bio to resume gene therapy trials
Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical tr... See more »
June 2, 2021BioSpace
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2021
bluebird bio, Inc. announced that the Compensation Committee of the Company's Board of Directors appr... See more »
May 21, 2021The Business Journals: Philadelphia
Spark Therapeutics sues gene therapy rival Bluebird Bio
The Philadelphia gene therapy company is in court over a Boston-area gene therapy firm's marketing ca... See more »
May 21, 2021MarketScreener
Among 51 patients treated with SKYSONA across clinical studies to date, there have been no reports of graft-versus-host disease (GVHD), graft failure or rejection, or transplant-related mortality (TRM) (Form 8-K)
(marketscreener.com) Among 51 patients treated with SKYSONA across clinical studies to date, there ha... See more »
May 19, 2021MarketScreener
Analysis of characteristics of neurotoxicity (NT) observed in KarMMa study reinforce well-understood safety profile of Abecma with mostly Grade 1/2 occurrences of NT having early onset and resolution (Form 8-K)
(marketscreener.com) Analysis of characteristics of neurotoxicity observed in KarMMa study reinforce ... See more »
bluebird bio Press Releases
April 13, 2021NewsFile
Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021
New York, New York--(Newsfile Corp. - April 13, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies i... See more »
April 13, 2021NewsFile
The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national sharehol... See more »
April 13, 2021NewsFile
Rosen, National Trial Counsel, Encourages bluebird bio, Inc. Investors with Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE
New York, New York--(Newsfile Corp. - April 13, 2021) - WHY: Rosen Law Firm, a global investor rights... See more »
April 11, 2021PR-Inside
Bronstein, Gewirtz & Grossman, LLC Reminds bluebird ...
(PR-inside.com) NEW YORK, NY / ACCESSWIRE / April 11, 2021 / Bronstein, Gewirtz & Grossman, LLC notif... See more »
April 9, 2021PR-Inside
The Schall Law Firm Announces the Filing of a ...
(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / April 9, 2021 / The Schall Law Firm, a national shareh... See more »
April 7, 2021StreetInsider
Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc
NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor righ... See more »
April 6, 2021PR-Inside
Levi & Korsinsky, LLP ...
(PR-inside.com) NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Levi & Korsinsky, LLP announces that clas... See more »
bluebird bio Videos
November 14, 2019bluebird bio Youtube Channel
"Chapter 1: Science, Genes - What does it all mean?" on YOUTUBE
Social Media
bluebird bio Headquarters
Trending Companies
IN THE NEWS
Fashionphile | ITW | Wind River Environmental | Porsche | AstraZeneca | Mirum | DIRECTV | Danaher | Paytm | HDFC | ChainLink | Suzlon | Cornell | TikTok | Schall Law Firm | GE | Industrial Adhesive Solutions | Reliance Retail | Aon | Alabama Power | United States Energy Association | Microsoft | Greif | Cedar | GoodRx | Urban Capital Network | S&W | Nokia | KeyBank | Allstate | P&G | Telford Homes | Kiadis | Cadence | Teladoc | WPX Energy | First Financial Bank | Midwest Retail Properties | Camden | Metlife | BD | Baltcom | Wipro | Lipocine | Bloomingdale's | Essex | EPAM | Builders FirstSource | Airbnb | Travelers
PEOPLE ALSO VIEWED
Fasteris | Sinensis Life Sciences | Nanofiber Solutions, LLC | DaVinci Biosciences | Kinnate Biopharma | Lilly Oncology | Entopsis | LSNE | Integrated Diagnostics | Pensieve Technology | Dipexium Pharmaceuticals | ActoKine Therapeutics | Nortis | Qvella | THB | Derventio Solutions | Queens Medical Imaging | GoTransit Media Group | dearJulius.com | On Bike Share | Agennix | Pasquali Srl | Abaranmp | Biozen Laboratories | BIOS Lighting | Tregren | J Hampstead | Locatory | Pajawi Investments | Pocket52
bluebird bio Summary
ABOUT
Overview
bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. bluebird bio was founded in 1992. bluebird bio's headquarters is located in Cambridge, Massachusetts, USA 02142. It has raised 526.4M in 8 rounds. The...
CEO
bluebird bio's President & CEO, Nick Leschly, currently has an approval rating of 73%. bluebird bio's primary competitors are Sangamo, Ember Therapeutics & Recombinetics.Website
bluebirdbio.comFrequently Asked Questions about bluebird bio
When was bluebird bio founded?
bluebird bio was founded in 1992Who is bluebird bio's CEO?
bluebird bio's CEO is Nick LeschlyHow much revenue does bluebird bio generate?
bluebird bio generates $241.7M in revenueHow much funding does bluebird bio have?
bluebird bio has historically raised $526.4M in funding
Where is bluebird bio's headquarters?
bluebird bio's headquarters is in Cambridge Massachusetts, USAHow many employees does bluebird bio have?
bluebird bio has 764 employeesWhat sector does bluebird bio operate in?
bluebird bio is in Biotechnology, PharmaceuticalsWho are bluebird bio's competitors?
bluebird bio's top competitors are Sangamo, Ember Therapeutics, Recombinetics
